Thallion Sells Stake in Caprion for $4.5M | GenomeWeb

NEW YORK (GenomeWeb News) – Thallion Pharmaceuticals today said that it has sold its remaining stake in Caprion Proteomics for approximately C$4.5 million (US$4.5 million).

The Montreal-based proteomics firm was sold by healthcare investment firm Great Point Partners to an affiliate of Chicago Growth Partners. The sale comes four years after Thallion sold an 80 percent interest in Caprion to Great Point.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.